Results 261 to 270 of about 218,137 (295)

Relationship between <i>Helicobacter pylori</i> infection and programmed death-ligand 1 in gastric cancer: A meta-analysis. [PDF]

World J Clin Oncol
Yang HC, Fu CF, Qiao LJ, Long GH, Yang LF, Yao B.   +5 more
europepmc   +1 more source

Therapeutic Applications of Programmed Death Ligand 1 Inhibitors in Small Cell Lung Cancer. [PDF]

Biomedicines
Nabipur L, Mouawad M, Venketaraman V.
europepmc   +1 more source

Pescadillo ribosomal biogenesis factor 1 and programmed death-ligand 1 in gastric and head and neck squamous cell carcinoma. [PDF]

World J Gastroenterol
Hu XN, Li CF, Huang SM, Nie CL, Pang R.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pan-cancer Landscape of Programmed Death Ligand-1 and Programmed Death Ligand-2 Structural Variations

JCO Precision Oncology, 2023
PURPOSE Programmed cell death protein-1 (PD-1) receptor and ligand interactions are the target of immunotherapies for more than 20 cancer types. Biomarkers that predict response to immunotherapy are microsatellite instability, tumor mutational burden, and programmed death ligand-1 (PD-L1) immunohistochemistry.
Emily L. Hoskins, Eric Samorodnitsky, Michele R. Wing, Julie W. Reeser, Julia F. Hopkins, Karthikeyan Murugesan, Zheng Kuang, Raven Vella, Leah Stein, Zachary Risch, Lianbo Yu, Serifat Adebola, Anoosha Paruchuri, John Carpten, Jad Chahoud, Stephen Edge, Jill Kolesar, Martin McCarter, Kenneth G. Nepple, Matthew Reilley, Courtney Scaife, Abhishek Tripathi, Nancy Single, Richard S.P. Huang, Lee A. Albacker, Sameek Roychowdhury   +25 more
openaire   +2 more sources

Programmed death ligand 1 signals in cancer cells

Nature Reviews Cancer, 2022
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to develop effective and revolutionary immunotherapies using antibodies blocking these cell-extrinsic interactions.
Anand V. R. Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel   +2 more
openaire   +2 more sources

The role of programed death-ligand 1 in renal diseases

Journal of Receptors and Signal Transduction, 2020
Programed death-ligand 1 (PD-L1, B7-H1, CD274) is a coinhibitory molecule that plays a vital role in the pathogenesis of both neoplastic and nonneoplastic diseases. However, the role of PD-L1 in primary and secondary renal diseases remains to be clarified.
Yi, Wei, Zongpei, Jiang
openaire   +2 more sources

Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget’s Disease

Anticancer Research, 2021
Extramammary Paget's disease (EMPD) is a type of carcinoma that usually progresses slowly but may cause metastasis and subsequent death of patients. We investigated the relationship between the expression of programmed death-ligand 1 (PD-L1)/programmed death-ligand 2 (PD-L2) and stromal CD8+ tumor-infiltrating lymphocytes (TILs) in EMPD and ...
Aya, Kawaguchi, Jun, Akiba, Reiichiro, Kondo, Eiji, Sadashima, Sachiko, Ogasawara, Yoshiki, Naito, Hironori, Kusano, Sakiko, Sanada, Ikko, Muto, Takekuni, Nakama, Hirohisa, Yano   +10 more
openaire   +2 more sources

Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma

Current Opinion in Oncology, 2015
The development of 'immune checkpoint inhibitors' or drugs targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has been a stunning success of cancer immunotherapy. This review provides a timely overview of the biology and function of the PD-1 pathway and discusses the rationale for therapeutic inhibition of this pathway in ...
Chan Yoon, Cheah, Nathan H, Fowler, Sattva S, Neelapu   +2 more
openaire   +3 more sources

Mind the target: programmed death ligand 1 in oesophagogastric cancers

Current Opinion in Oncology, 2022
Purpose of review Metastatic oesophagogastric cancers carry a prognosis of generally less than 2 years despite current treatment. There has been recent excitement in the field focused on immune checkpoint inhibition though anti-PD-1 antibodies.
Luke A, Wylie, Harriet C, Baker, Elizabeth C, Smyth   +2 more
openaire   +2 more sources